InsidersTradesSigma
申报总数
公司
▲ 买入（1 笔）
▼ 卖出（0 笔）
内部人交易记录
董事已披露买入
1
已披露卖出
0
T+90 胜率
0%
T+90 平均收益
-42.0%
基于 1 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
信号历史
Explore the full record of transactions filed by Hoberman Kenneth, 董事. Director active across 3 companies, notably TG Therapeutics, INC.. Cumulatively, 10 disclosures have been logged. Split: 1 buy · 0 sell. Total volume traded: €101k. Activity tracked since 18 June 2021. The latest transaction was filed on 12 June 2025 (Attribution). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to Hoberman Kenneth
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报10 总计
14,718 股0Common StockSEC:0001437749-25-020543:0
30,000 股0Common StockSEC:0001104659-25-058915:0
22,250 股0Common StockSEC:0001437749-24-020849:0
30,000 股0Common StockSEC:0001104659-24-071285:0
20,000 股0Common StockSEC:0001104659-23-105394:0
18,000 股0Common StockSEC:0001104659-23-072605:0
43,732 股0Common StockSEC:0001104659-22-082020:0
6,000 股@ US$17.40100.0% 占其流量Common StockSEC:0001104659-22-060913:0
标准退出：2022年8月10日 (T+90)
20,000 股0COMMON STOCKSEC:0001104659-21-084258:0
150,000 股Common StockSEC:0001104659-16-089212:0
10 条申报中的 10 条
About Hoberman Kenneth
Hoberman Kenneth is Administrateur at TG Therapeutics, INC. and Nuvectis Pharma, Inc., and Chief Operating Officer at STEMLINE THERAPEUTICS INC. He has 10 filings in total, and across the 10 sampled filings, the period runs from 2016-01-11 to 2025-06-16, with EUR 100582 of purchases and EUR 0 of sales, and the most frequent transaction nature is Attribution.
